Care After Biomedicine’s Edge: Cannabis and Psilocybin for Cancer Patients

September 23, 2026
By RN Collins

Read more about cannabis, psilocybin, and cancer patients in the Cancer edition of Fat Nugs Magazine

What it means that cancer patients are reaching for cannabis and psilocybin — and what medicine is finally beginning to hear

Modern cancer medicine can do things that would have been unimaginable 50 years ago. Survival rates for once fatal cancers have improved dramatically. The machinery of biomedical cancer research has earned its reputation as among the most sophisticated in human history.

And yet: somewhere between 25 and 40% of people in active cancer treatment are using cannabis, mostly without clinical guidance, mostly without telling their doctors.

A growing number are seeking psilocybin-assisted therapy for the depression, anxiety, and existential distress their diagnosis and treatment have produced — in a legal environment that makes access difficult and a clinical environment that has only recently begun to develop formal guidance on either.

The question worth asking is what they are reaching for, and why.

The Gap Between Medicine and Cancer Patients Is Real

Biomedicine is excellent at several things relevant to cancer care: identifying cancer, characterizing it molecularly, targeting it pharmacologically, monitoring its response to treatment, and — with increasing success — achieving remission or cure.

What it has historically been less excellent at is everything that happens to the person who has cancer while all of that is occurring.

Up to 90% of people undergoing active cancer treatment report unmet needs, with psychological and physical symptom challenges most prevalent. These are not niche complaints — they are the majority experience. The nausea, the sleep disruption, the pain, the fear, the grief, the loss of identity that comes with a cancer diagnosis are near-universal experiences that standard oncology care addresses with a toolkit that is adequate for some patients and inadequate for most.

Integrative Oncology Tries to Bridge The Gap

The rise of integrative oncology as a formal discipline is partly medicine’s self-correction in response to this gap. A majority of NCI-designated cancer centers now offer acupuncture, massage, meditation, and nutrition counseling alongside conventional treatment.

The Society for Integrative Oncology and ASCO have published joint guidelines on evidence-based integrative approaches. The field has recognized that treating cancer without treating what it does to the person having it is inadequate medicine.

The history of integrative oncology is instructive for how to think about where cannabis and psilocybin are now. Acupuncture for cancer pain, mind-body interventions for anxiety, and yoga for fatigue were all patient-driven before they were evidence-based.

The Rise of Cannabis and Psilocybin for Cancer Patient Care

The institutional response followed patient behavior rather than preceding it. That trajectory — patient-driven to evidence-informed to institutionally integrated — is the path cannabis and psilocybin are on, with the complication that legal barriers have slowed the evidence phase in ways acupuncture did not face.

Cannabis and psilocybin are the next layer of that— further from the mainstream than acupuncture or meditation, entangled in legal complexity those modalities are not, and carrying historical stigma that complicates the clinical conversation.

But the thing bringing patients to them is the same thing that brought patients to integrative oncology before the evidence base existed: the gap between what they need and what is being offered.

What Cancer Patients Are Actually Saying About Cannabis and Psilocybin

The NCI-funded survey of cannabis use across 12 cancer centers asked patients why they use cannabis. The answers form a list: sleep, pain, mood and anxiety, stress, treatment side effects.

These are quality-of-life domains that have historically been undertreated in cancer care. Cannabis has become one patient-driven attempt to fill this gap. The patients using cannabis for sleep are not making an ideological statement. They are trying to sleep.

The patients seeking psilocybin-assisted therapy are saying something different: that the psychological and existential dimension of their illness — the fear, the altered sense of time, the disrupted relationship with meaning and mortality — is not being adequately addressed by their care team. They are finding a research literature describing rapid, durable shifts in relationship to illness and death in patients like them, and trying to access that.

Cancer Patients Seek More Comprehensive Care

Both substances are forms of patient agency in the face of a care system that has historically asked patients to be passive recipients of biomedical intervention.

The patient who tries cannabis for nausea without telling their oncologist is making a decision their oncologist was not positioned to help with. The patient who drives to an Oregon psilocybin service center is deciding that home-state access constraints matter less than relief from depression antidepressants have not provided. These are rational decisions made where the sanctioned options have been insufficient.

The disclosure gap deserves more than a statistic. The same multicenter survey data documents why patients do not tell their oncologists about cannabis use: fear of provider judgment, an expectation the provider will not have useful information, and genuine ambiguity about whether it needs to be disclosed alongside prescription medications.

These are rational responses to a clinical environment that has historically been dismissive of cannabis questions. The communication failure belongs to the healthcare system as much as the patient. Closing the gap requires providers to establish, at the start, that they want to know, will not judge it, and need the information for interaction screening.

The Importance of Patient Disclosure

Cannabis used without disclosure can interact with active cancer treatments in ways patients are not positioned to screen for themselves, and managing significant psychological distress with self-directed cannabis use may delay an evaluation that warrants direct oncological or psychiatric attention.

The patient driving to Oregon for psilocybin outside a clinical trial does not have the preparation, integration support, contraindication screening, or safety monitoring the clinical protocol provides.

These are not reasons to dismiss patient agency, but reasons to name the specific risks that accompany self-directed use of both substances.

What the Evidence Is Starting to Show in Cannabis and Psilocybin for Cancer Patients

The evidence for cannabis in cancer care is real but limited. The 2024 ASCO guidelines found the strongest support for refractory chemotherapy-induced nausea and vomiting, and insufficient evidence across most other symptom domains.

That “insufficient evidence” finding describes the state of the research, not a verdict on whether cannabis helps people. The Schedule I classification has made research structurally difficult for decades, a large part of why the evidence is not where it should be for a substance used by 25 to 40% of cancer patients in active treatment.

The evidence for psilocybin-assisted therapy in cancer-related psychological and existential distress is more compelling in quality, if smaller in scale.

The 2016 Hopkins and NYU trials found rapid, durable reductions in depression and anxiety that persisted at six months and, in the NYU follow-up, at more than four years. A 2025 meta-analysis across 15 studies confirmed large effect sizes with acceptable safety profiles. Palliative care and oncology are beginning to take these findings seriously at the level of clinical guidelines and research funding.

Different Substances, Similar Paths Forward

What both bodies of evidence share is a pattern: patients reaching for something beyond the biomedical toolkit, finding it clinically useful, and research slowly catching up to confirm what patients were already experiencing. It is a familiar pattern from integrative oncology, which spent years building the evidence base for interventions patients were already using.

The methodological shift happening in parallel is itself significant. The FDA’s 2024 guidance on core patient-reported outcomes in cancer clinical trials formally established that what patients experience — their symptoms, functional status, quality of life — is clinical data, not a secondary concern.

That shift matters for cannabis and psilocybin research, because the outcomes that matter most for these interventions are exactly the patient-reported ones: does the patient sleep better, feel less afraid, regain some sense of meaning? The trial infrastructure now being built around both is increasingly designed to capture those outcomes as primary endpoints.

What Medicine Is Beginning to Hear

The publication of the 2024 ASCO cannabis guidelines was itself a form of institutional listening.

For the first time, a major U.S. oncology organization formally acknowledged that:

Cannabis use among cancer patients is substantial
Patients need clinical guidance
Providers have an obligation to engage with cannabis questions rather than avoid them

The guidelines are imperfect, but their existence represents a significant shift in oncology’s institutional posture.

The FDA’s breakthrough therapy designations for psilocybin-assisted therapy in treatment-resistant depression, and the active phase 3 trials those designations have enabled, signal a similar shift in the psychedelic space. The National Cancer Institute’s funding of prospective studies aimed at cannabis evidence gaps in oncology represents institutional investment in closing the research deficit decades of Schedule I classification produced.

The structural barriers that created the gap deserve more than an implicit reference to Schedule I status. U.S. healthcare’s reimbursement architecture creates no financial incentive for oncologists to develop cannabis counseling expertise, since that conversation is not separately billable.

The physician training pipeline does not include cannabis pharmacology or psychedelic-assisted therapy in standard oncology curricula, and malpractice frameworks create liability ambiguity that physicians have navigated piecemeal. Addressing this requires structural changes — curriculum reform, CPT code development, liability clarification — not only cultural shifts.

These are not dramatic reversals. They are incremental movements toward a clinical culture that treats what patients are already doing as data rather than deviation, and that builds the evidence and guidance infrastructure to serve those patients well.

The pace of that movement is frustratingly slow relative to the pace of patients’ needs. The 25 to 40% of cancer patients using cannabis today are using it largely without clinical guidance. The infrastructure that would serve them well is still being built.

Where Things Are Heading for Cannabis, Psilocybin, and Cancer Patients

The legal landscape for both cannabis and psilocybin continues to move toward expanded access, imperfectly and unevenly.

Cannabis is legal in some form in 48 states, following Nebraska’s 2024 voter approval of medical cannabis; Idaho and Kansas remain the only states with complete prohibition.
Psilocybin has regulated access in Oregon, Colorado, and New Mexico, and is the subject of active federal rescheduling conversations.

Neither substance has the clinical infrastructure that would allow it to function as a mainstream component of cancer care.

The patient agency framing has an equity problem the literature rarely names. The cancer patient who drives to an Oregon psilocybin service center needs geographic access, time off work, transportation, and several hundred to several thousand dollars for a session no insurance plan covers. The 25 to 40% of cancer patients already using cannabis skews toward those with legal access, financial means, and geographic proximity to licensed dispensaries — not toward the full population of patients for whom it might be relevant.

Cancer treatment produces financial toxicity for many patients. Complementary interventions with significant out-of-pocket costs compound that burden unevenly.

A dying patient with refractory existential distress who cannot access psilocybin-assisted therapy because the nearest trial site is three states away is not a policy abstraction — it is a clinical justice problem that belongs in any serious conversation about where these interventions fit in cancer care.

The Impending Federal Hemp Ban

One near-term change is worth naming concretely. Federal legislation enacted in November 2025 established new statutory definitions for hemp-derived cannabinoid products and imposes a strict total-THC limit taking effect in November 2026.

Most full-spectrum hemp-derived products — including many CBD oils and capsules patients in states without comprehensive medical cannabis programs have relied on — will be removed from lawful commerce. Patients using these products as a workaround to limited access should know that state medical cannabis programs are the more durable pathway going forward.

Cancer Patients Won’t Wait For Agencies or Doctors to Catch Up

What is already clear is that patients will not wait for that infrastructure before deciding whether these tools help them. They are making that decision now, with or without clinical guidance, legal access, or their oncologists’ knowledge.

The question is whether medicine will build the infrastructure to serve those patients well — with accurate information, safety monitoring, and integration with the broader oncology care plan — or whether patients will continue navigating this terrain without support.

The answer depends partly on research funding, partly on institutional will, and partly on the willingness of individual clinicians to engage with questions their training did not prepare them for.

The ASCO guideline on cannabis is a starting point. The research program being built around psilocybin in cancer populations is a starting point. The clinical infrastructure — the trained workforce, the institutional protocols, the coverage frameworks — is the harder work ahead.

Schedule III or Illegal?

On the regulatory side, a December 2025 executive order directed the DEA and HHS to expedite the rescheduling process for cannabis, which — if completed — would move it from Schedule I to Schedule III. This would not federally legalize cannabis, but it would formally recognize medical value, ease research restrictions, and reduce the 280E tax burden on cannabis businesses.

For oncology research specifically, rescheduling would significantly lower the administrative barriers to studying cannabis in cancer populations. The process is not complete and faces legal complexity, but the trajectory is the clearest it has been since cannabis was placed in Schedule I.

How Clinicians Can Embrace Cannabis and Psilocybin for Cancer Patients

What clinicians can do now, without waiting for that infrastructure, is concrete: ask.

Ask about cannabis use at every major care transition, using a non-judgmental frame. Document what patients are using — product, route, dose, frequency — alongside prescription medications, and screen for interaction risk with the active drug regimen. For patients interested in psilocybin-assisted therapy, provide an honest summary of the evidence and name searchable trial registries (ClinicalTrials.gov, the MAPS participant registry). For patients using cannabis without guidance, open the pharmacological conversation: which symptoms they’re targeting, whether the current approach is helping, what routes or ratios are worth considering.

The cost of that infrastructure gap is worth naming. A cancer patient using cannabis from an informal source is using an unregulated product of unknown composition, without interaction screening or dosing guidance. A dying patient who cannot access psilocybin-assisted therapy because no trial site is within reach is experiencing preventable suffering the evidence shows is addressable. These are not abstract policy failures — they are the daily reality of people managing a devastating illness with the tools available to them.

Cancer care has always been shaped by patients who needed more than the system was offering. What is different now is that the evidence base is beginning to articulate precisely what they were reaching for and why.

Cannabis is filling symptom management gaps that inadequate supportive care created; psilocybin is addressing existential and psychological burden that standard psychiatry has not been equipped to treat.

Both are doing this without the clinical infrastructure that would make them safer, more accessible, and more equitably distributed. The question for medicine is whether the field meets patients with the evidence and structural investment their situation demands — or continues to require them to cross that distance alone.

About the Author

RN Collins is the staff writer at Fat Nugs Magazine, as well as 1L at Northeastern University School of Law and a neuroscientist exploring how brain health and the environment intersect. Through her writing, she bridges academic research and science communication to reframe how psychoactive plants and other traditional and alternative medicines are understood. She’s building a career that connects law, technology, and creativity—and welcomes conversations and opportunities across fields that share that vision. Connect with her on LinkedIn!

Subscribe to Fat Nugs Magazine!

Love this article? Show your support for Fat Nugs with a magazine subscription!

As a fully independent media organization, Fat Nugs relies on the grassroots support of individuals like you to continue to write and share these articles. Every subscription helps us keep bringing you the unbiased, broad-ranging cannabis, hemp, and psychedelics articles like these.